Filtered By:
Specialty: Epidemiology
Condition: Bleeding

This page shows you your search results in order of date.

Order by Relevance | Date

Total 27 results found since Jan 2013.

Thromboembolic events, bleeding, and mortality in patients with cerebral venous thrombosis: a nationwide cohort study
We examined the clinical course of patients with CVT overall and according to age and sex. Using Danish registries, we identified all patients with a first-time primary inpatient diagnosis of CVT from 1996 to 2018 (N = 653, median age 41 years, 67% women) and individuals from the general population, matched on age, sex, and calendar year (N = 65,300). Patients with CVT were at increased risk of venous thromboembolism (VTE) in other sites, ischemic stroke, major bleeding, and mortality. For both sexes, the increased risks of VTE in other sites were most prominent among the young (18-54 years), while the increased risks of i...
Source: Adv Data - September 16, 2022 Category: Epidemiology Authors: Nils Skajaa Jan Vandenbroucke Claus Ziegler Simonsen Henrik Toft Toft S ørensen Kasper Adelborg Source Type: research

Incidence and Severity of Intracerebral Hemorrhage on Oral Anticoagulation and Antiplatelet Therapy
This study aimed to assess the occurrence of intracerebral hemorrhage (ICH) in patients using OA or AP registered in the JOINVASC between 2015 and 2020. Higher mortality among OA or AP patients was seen, with a statistically significant difference in mortality within 90 days (38% versus 25%, p=0.025). For patients with OA at the time of ICH, high stroke severity was observed, with a 71% mortality rate. Managing bleeding episodes on OA and AP is key in the effort to prevent cardiovascular death and disability, and improved access to DOAC and reversal agents is in need for this patient population.
Source: Neuroepidemiology - June 27, 2022 Category: Epidemiology Source Type: research

XaMINA: A Real-World, Prospective, Observational Study of Treatment-Na ïve Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation in Asia
CONCLUSION: XaMINA demonstrated low incidence rates of major bleeding events and thromboembolic events in patients with NVAF newly initiating rivaroxaban in South Korea and Taiwan, consistent with previous real-world studies reconfirming the results of the ROCKET AF study.TRIAL REGISTRATION: The trial was registered on ClinicalTrials.gov (identifier NCT03284762) on 15 September 2017.PMID:35616848 | DOI:10.1007/s12325-022-02102-8
Source: Adv Data - May 26, 2022 Category: Epidemiology Authors: Ping-Yen Liu Eue-Keun Choi Tae-Seok Kim Jen-Yuan Kuo Jung Myung Lee Young Keun On Sang-Weon Park Hyung-Wook Park Dong-Gu Shin Lili Wang Hsueh-Wei Yen Moon-Hyoung Lee XaMINA Investigators Source Type: research

Direct oral anticoagulation in atrial fibrillation and heart valve surgery-a meta-analysis and systematic review
CONCLUSION: Cumulative data analysis reveals that DOAC may provide an effective and safe alternative to VKA in patients with AF after surgically implanted bioprosthetic heart valves or repair with AF. Within a relatively heterogeneous study population, this meta-analysis shows a risk reduction of major bleedings and thromboembolic stroke or systemic embolisms for DOAC.PMID:35481366 | DOI:10.1177/17539447221093963
Source: Adv Data - April 28, 2022 Category: Epidemiology Authors: Stephen Gerfer Ilija Djordjevic Kaveh Eghbalzadeh Navid Mader Thorsten Wahlers Elmar Kuhn Source Type: research

Comparison of Net Clinical Benefit Between Clopidogrel and Ticagrelor Following Percutaneous Coronary Intervention in Patients in China With Acute Coronary Syndrome
CONCLUSION: In Chinese ACS patients who underwent PCI with second-generation DESs, outpatient use of clopidogrel dual antiplatelet therapy (DAPT) was associated with reduction in NACCE and bleeding.PMID:34904209 | DOI:10.1007/s12325-021-01907-3
Source: Adv Data - December 14, 2021 Category: Epidemiology Authors: Dandan Li Yang Sun Xiaoran Ye Lanting Li Yundai Chen Daowen Wang Source Type: research

Comparative effectiveness and safety of direct acting oral anticoagulants in nonvalvular atrial fibrillation for stroke prevention: a systematic review and meta-analysis
Conclusions: Apixaban appeared to have a favorable effectiveness-safety profile compared with the other DOACs in AF for stroke prevention, based on evidence from both direct and indirect comparisons. However, additional high-quality evidence is needed to support firm recommendations on clinical decision-making.
Source: European Journal of Epidemiology - August 1, 2021 Category: Epidemiology Source Type: research

Evidence Of The Different Associations Of Prognostic Factors With Censoring Across Treatment Groups And Impact On Censoring Weight Model Specification: The Example Of Anticoagulation In Atrial Fibrillation
Am J Epidemiol. 2021 Jun 24:kwab186. doi: 10.1093/aje/kwab186. Online ahead of print.ABSTRACTInverse probability of censoring weights (IPCWs) may reduce selection bias due to informative censoring in longitudinal studies. However, in studies with an active comparator, the associations between predictors and censoring may differ across treatment groups. We used the clinical example of anticoagulation treatment with warfarin or a direct oral anticoagulant (DOAC) in atrial fibrillation to illustrate this. The cohort of individuals initiating an oral anticoagulant during 2010-2016 was identified from the Régie de l'assurance ...
Source: Am J Epidemiol - June 24, 2021 Category: Epidemiology Authors: Liliya Sinyavskaya Mireille Schnitzer Christel Renoux Jason R Guertin Denis Talbot Madeleine Durand Source Type: research

Comparative effectiveness and safety of direct acting oral anticoagulants in nonvalvular atrial fibrillation for stroke prevention: a systematic review and meta-analysis
Conclusions: Apixaban appeared to have a favorable effectiveness-safety profile compared with the other DOACs in AF for stroke prevention, based on evidence from both direct and indirect comparisons. However, additional high-quality evidence is needed to support firm recommendations on clinical decision-making.
Source: European Journal of Epidemiology - May 15, 2021 Category: Epidemiology Source Type: research

Different Risk Profiles of European Patients Using Direct Oral Anticoagulants or Vitamin K Antagonists: a Rapid Review
AbstractPurpose of ReviewWe investigated the risk profiles of patients using direct oral anticoagulants (DOAC) or vitamin K antagonists (VKA) in European cohort studies to estimate the importance of potential (measured or unmeasured) confounding factors in analyses comparing these drugs. We searched MEDLINE and EMBASE (2008 –2018) for relevant studies and extracted information on age, sex, comorbidity, Charlson comorbidity index, HAS-BLED score (assessing risk of bleeding) and CHA2DS2-VASc score (assessing risk of stroke).Recent FindingsOverall, 66 studies with 2,808,757 patients were included. Most patients were from Fr...
Source: Current Epidemiology Reports - November 14, 2020 Category: Epidemiology Source Type: research

Reweighting Oranges to Apples: Transported RE-LY Trial Versus Nonexperimental Effect Estimates of Anticoagulation in Atrial Fibrillation
Conclusions: Differences in study populations can and should be considered quantitatively to ensure results are relevant to populations of interest, particularly when comparing trial with nonexperimental findings. See video abstract: http://links.lww.com/EDE/B703.
Source: Epidemiology - July 31, 2020 Category: Epidemiology Tags: Cardiovascular Disease Source Type: research

Using the Case-Crossover Design to Assess Short-Term Risks of Bleeding and Arterial Thromboembolism After Switching Between Oral Anticoagulants in a Population-Based Cohort of Patients With Atrial Fibrillation
AbstractUsing nationwide Danish registries, we conducted a population-based case-crossover study evaluating the association between switching from a vitamin K antagonist (VKA) to a direct oral anticoagulant (DOAC), and vice versa, and 30-day risks of bleeding and arterial thromboembolism in patients with atrial fibrillation (AF). The case-crossover population was identified among oral anticoagulant users during 2011 –2018 (n = 123,217) as patients with AF with 1) a case-defining outcome and 2) an anticoagulant switch during the 180 days preceding the outcome. Odds ratios were estimated using conditional logistic regres...
Source: American Journal of Epidemiology - July 8, 2020 Category: Epidemiology Source Type: research